We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Dechra Pharmaceuticals Plc | LSE:DPH | London | Ordinary Share | GB0009633180 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3,866.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMDPH
RNS Number : 9129U
Dechra Pharmaceuticals PLC
03 April 2019
The information contained within this announcement contains inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
Wednesday, 3 April 2019
Dechra(R) Pharmaceuticals PLC
("Dechra" or "the Company")
Directorate Change
Dechra announces that Richard Cotton, the Company's Chief Financial Officer, has informed the Board of his decision to leave the Company immediately for personal reasons.
The Board has agreed that with immediate effect Richard will resign as Director and relinquish his current responsibilities but remain available to the Group until 28 June 2019. The Company would like to thank Richard for his contribution during his service and wish him well for the future.
The search process for a replacement has commenced and a further update on this will be made in due course. In the interim period, Paul Sandland, DVP EU Finance Director, will assume the role of Acting Chief Financial Officer until a permanent successor to Richard is appointed.
Trading across the Group has continued to witness growth and is in line with management expectations as we stated in the Half Year results released last month.
The Company expects to release its next Trading update in July, ahead of its Annual results scheduled for publication in September.
Hot Features
Premium
Enquiries:
Dechra Pharmaceuticals PLC
Ian Page, Chief Executive Officer Office: +44 (0) 1606
814 730
e-mail: corporate.enquiries@dechra.com
TooleyStreet Communications Ltd
Fiona Tooley, Director Mobile: +44 (0) 7785
e-mail: fiona@tooleystreet.com 703 523
Office: +44 (0) 121
309 0099
About Dechra
Dechra is an international specialist veterinary pharmaceuticals and related products business. Its expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
BOALFFLISRIFIIA
(END) Dow Jones Newswires
April 03, 2019 02:01 ET (06:01 GMT)
1 Year Dechra Pharmaceuticals Chart |
1 Month Dechra Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
